Indicators on BCAT-IN-4 You Should Know
The key end place was the protection and tolerability of sifalimumab. Cure-emergent adverse activities (AEs) and major AEs (SAEs) as well as their severity, final result, and any romance to your analyze medication ended up recorded from the investigator through the study. AEs were being deemed very likely to be connected with study medication whene